1
|
Kamlo Kamso VF, Dongmo Melogmo YK, Tchegnitegni BT, Tchatat Tali MB, Dize D, Ngansop CN, Ambassa P, Ouete Nantchouang JL, Konga IS, Boyom FF, Ngadjui BT, Fotso GW. New lignan glycosides from Justicia secunda Vahl (Acanthaceae) with antimicrobial and antiparasitic properties. Heliyon 2023; 9:e22897. [PMID: 38125494 PMCID: PMC10730754 DOI: 10.1016/j.heliyon.2023.e22897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2023] [Revised: 11/21/2023] [Accepted: 11/22/2023] [Indexed: 12/23/2023] Open
Abstract
Three new lignan glucosides, namely, justisecundosides A (1), B (2a), and C (2b), were isolated from the whole plant of Justicia secunda together with seven known compounds (3-9). Their structures were established based on a comprehensive analysis of HR-ESI-MS, IR, UV, and CD, in conjunction with their 1D and 2D-NMR data. A putative biogenetic pathway of compounds 1-2a,b from coniferyl alcohol was proposed. In addition, the antimicrobialactivities of the extract, fractions, and some isolated compounds were assessed against multiresistant bacterial and fungal strains. Furthermore, the antiplasmodial, antileishmanial, and antitrypanosomal activities were assessed against the sensitive (3D7) and multidrug-resistant (Dd2) strains of P. falciparum, promastigote and bloodstream forms of L. donovani, and Trypanosoma brucei, respectively. Compound 4 exhibited moderate antibacterial activity against Staphylococcus aureus SA RN 46003 with a MIC value of 62.5 μg/mL. Besides, compound 6 demonstrated a very good activity against sensitive (IC50Pf3D7: 0.81 μg/mL) and multidrug-resistant (IC50PfDd2: 14.61 μg/mL) strains of P. falciparum while compound 4 displayed good antitrypanosomal activity (IC50: 1.19 μg/mL). Also, compound 1 was the most active on the promastigote form of L. donovani with an IC50 of 13.02 μg/mL.
Collapse
Affiliation(s)
- Viviane Flore Kamlo Kamso
- Department of Organic Chemistry, Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon
| | | | | | | | - Darline Dize
- Department of Biochemistry, Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon
| | - Cyrille Njampa Ngansop
- Department of Biochemistry, Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon
| | - Pantaléon Ambassa
- Department of Organic Chemistry, Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon
| | | | - Ingrid Simo Konga
- Department of Chemistry, Faculty of Science, University of Dschang, P.O. Box 67, Dschang, Cameroon
| | - Fabrice Fekam Boyom
- Department of Biochemistry, Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon
| | - Bonaventure Tchaleu Ngadjui
- Department of Organic Chemistry, Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon
- University Institute of Sciences, Technologies and Ethics, P.O. Box 30201, Yaoundé, Cameroon
| | - Ghislain Wabo Fotso
- Department of Organic Chemistry, Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon
| |
Collapse
|
2
|
Saayman M, Kannigadu C, Aucamp J, Janse van Rensburg HD, Joseph C, Swarts AJ, N'Da DD. Design, synthesis, electrochemistry and anti-trypanosomatid hit/lead identification of nitrofuranylazines. RSC Med Chem 2023; 14:2012-2029. [PMID: 37859713 PMCID: PMC10583827 DOI: 10.1039/d3md00220a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Accepted: 08/12/2023] [Indexed: 10/21/2023] Open
Abstract
Chagas disease and leishmaniasis are vector-borne infectious diseases affecting both humans and animals. These neglected tropical diseases can be fatal if not treated. Hundreds to thousands of new Chagas disease and leishmaniasis cases are being reported by the WHO every year, and currently available treatments are insufficient. Severe adverse effects, impractical administrations and increased pathogen resistance against current clinical treatments underscore a serious need for the development of new drugs to curb these ailments. In search for such drugs, we investigated a series of nitrofuran-based azine derivatives. Herein, we report the design, synthesis, electrochemistry, and biological activity of these derivatives against promastigotes and amastigotes of Leishmania major, and L. donovani strains, as well as epimastigotes and trypomastigotes of Trypanosoma cruzi. Two leishmanicidal early leads and one trypanosomacidal hit with submicromolar activity were uncovered and stand for further in vivo investigation in the search for new antitrypanosomatid drugs. Future objective will focus on the identification of involved biological targets with the parasites.
Collapse
Affiliation(s)
- Maryna Saayman
- Centre of Excellence for Pharmaceutical Sciences, North-West University Potchefstroom 2520 South Africa +27 18 299 4243 +27 18 299 2256
| | - Christina Kannigadu
- Centre of Excellence for Pharmaceutical Sciences, North-West University Potchefstroom 2520 South Africa +27 18 299 4243 +27 18 299 2256
| | - Janine Aucamp
- Centre of Excellence for Pharmaceutical Sciences, North-West University Potchefstroom 2520 South Africa +27 18 299 4243 +27 18 299 2256
| | - Helena D Janse van Rensburg
- Centre of Excellence for Pharmaceutical Sciences, North-West University Potchefstroom 2520 South Africa +27 18 299 4243 +27 18 299 2256
| | - Cassiem Joseph
- Molecular Sciences Institute, School of Chemistry, University of the Witwatersrand Johannesburg-Braamfontein 2050 South Africa
| | - Andrew J Swarts
- Molecular Sciences Institute, School of Chemistry, University of the Witwatersrand Johannesburg-Braamfontein 2050 South Africa
| | - David D N'Da
- Centre of Excellence for Pharmaceutical Sciences, North-West University Potchefstroom 2520 South Africa +27 18 299 4243 +27 18 299 2256
| |
Collapse
|
3
|
Ribeiro A, Serrano R, da Silva IBM, Gomes ET, Pinto JF, Silva O. The Genus Diospyros: A Review of Novel Insights into the Biological Activity and Species of Mozambican Flora. PLANTS (BASEL, SWITZERLAND) 2023; 12:2833. [PMID: 37570987 PMCID: PMC10421099 DOI: 10.3390/plants12152833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 07/21/2023] [Accepted: 07/29/2023] [Indexed: 08/13/2023]
Abstract
Species of the Diospyros L. genus (Ebenaceae family) have been largely used in traditional medicine for the treatment of several diseases, especially infectious ones. To date, active major compounds such as naphthoquinones, triterpenoids, and tannins have been isolated and pharmacologically validated from Diospyros species. The present study summarizes the information available in the literature on the species described in the Flora of Mozambique. To do so, scientific databases (e.g., PubMed, Scopus, Web of Science, and Google Scholar) were searched using various keywords and Boolean connectors to gather and summarize the information. Of the 31 native and naturalized species in the Flora of Mozambique, 17 are used in different regions of Africa and were described for their traditional uses. They were reported to treat more than 20 diseases, mostly infectious, in the gastrointestinal and oral cavity compartments. This work provides an overview of the therapeutical potential of Diospyros species and explores novel insights on the antimicrobial potential of extracts and/or isolated compounds of these Mozambican species.
Collapse
Affiliation(s)
| | | | | | | | | | - Olga Silva
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal; (A.R.); (R.S.); (I.B.M.d.S.); (E.T.G.); (J.F.P.)
| |
Collapse
|
4
|
Guzmán C, Villalobos N, Ortiz Caltempa A, Hernández M, Núñez G, Salazar J, Bobes RJ, Fragoso G, Sciutto E, Villarreal ML. In Vitro and In Vivo Cysticidal Effects of Carica Papaya Cell Suspensions. Infect Immun 2023; 91:e0051722. [PMID: 37341599 PMCID: PMC10353365 DOI: 10.1128/iai.00517-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2022] [Accepted: 05/24/2023] [Indexed: 06/22/2023] Open
Abstract
Parasitic diseases are a major public health problem worldwide. Plant-derived products appear to be ideal candidates from a biotechnological perspective, being sustainable and environmentally friendly. The antiparasitic properties of Carica papaya have been attributed to some of its components, including papain and other compounds that are concentrated in the latex and seeds. This study demonstrated in vitro a high and insignificantly different cysticidal activity of soluble extract that was obtained after the disruption of nontransformed wild-type (WT) cells as well as transformed papaya calluses (PC-9, PC-12, and PC-23) and papaya cell suspensions (CS-9, CS-12, and CS-23). In vivo, cell suspensions of CS-WT and CS-23 that had been previously lyophilized were tested with respect to their cysticidal effects, compared with those of three commercial antiparasitic drugs. CS-WT and CS-23 together reduced the number of cysticerci, the number of buds, and the percentage of calcified cysticerci in a similar extent to albendazole and niclosamide, whereas ivermectin was less effective. Mice were then orally immunized with CS-23 that expressed the anti-cysticercal KETc7 antigen (10 μg/mouse), CS-WT (10 mg/mouse), or both together to evaluate their preventive properties. CS-23 and CS-WT significantly reduced the expected parasite and increased the percentage of calcified cysticerci as well as recovery, being more effective when employed together. The results reported in this study support the feasibility of the development of an anti-cysticercosis vaccine from cells of C. papaya in in vitro cultures, as they are a source of an anthelmintic, natural, and reproducible product.
Collapse
Affiliation(s)
- Cynthia Guzmán
- Biotechnology Research Center, Autonomous University of the State of Morelos, Cuernavaca, Morelos, Mexico
- Department of Immunology, Instituto de Investigaciones Biomédicas. Universidad Nacional Autónoma de México, Ciudad de México, Mexico
| | - Nelly Villalobos
- Department of Pathology, Faculty of Veterinary Medicine and Zootechnics, National Autonomous University of Mexico, Ciudad Universitaria. Alcaldia Coyoacan, Mexico City, Mexico
| | - Anabel Ortiz Caltempa
- Biotechnology Research Center, Autonomous University of the State of Morelos, Cuernavaca, Morelos, Mexico
| | - Marisela Hernández
- Department of Immunology, Instituto de Investigaciones Biomédicas. Universidad Nacional Autónoma de México, Ciudad de México, Mexico
| | - Guadalupe Núñez
- Faculty of Veterinary Medicine and Zootechnics, Academic Unit No. 2, Autonomous University of Guerrero, Cuajinicuilapa, Guerrero, Mexico
| | - Juan Salazar
- Research Direction, La Salle University, Mexico City, Mexico
| | - Raúl José Bobes
- Department of Immunology, Instituto de Investigaciones Biomédicas. Universidad Nacional Autónoma de México, Ciudad de México, Mexico
| | - Gladis Fragoso
- Department of Immunology, Instituto de Investigaciones Biomédicas. Universidad Nacional Autónoma de México, Ciudad de México, Mexico
| | - Edda Sciutto
- Department of Immunology, Instituto de Investigaciones Biomédicas. Universidad Nacional Autónoma de México, Ciudad de México, Mexico
| | - María Luisa Villarreal
- Biotechnology Research Center, Autonomous University of the State of Morelos, Cuernavaca, Morelos, Mexico
| |
Collapse
|
5
|
Ndlovu K, Kannigadu C, Aucamp J, van Rensburg HDJ, N'Da DD. Exploration of ethylene glycol linked nitrofurantoin derivatives against Leishmania: Synthesis and in vitro activity. Arch Pharm (Weinheim) 2023; 356:e2200529. [PMID: 36759973 DOI: 10.1002/ardp.202200529] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Revised: 11/27/2022] [Accepted: 12/30/2022] [Indexed: 02/11/2023]
Abstract
Leishmaniasis is a neglected tropical disease that is caused by the Leishmania parasite. It is estimated that there are more than 350 million people at risk of infection annually. Current treatments that are in clinical use are expensive, have toxic side effects, and are facing parasitic resistance. Therefore, new drugs are urgently required. In the quest for new, safe, and cost-effective drugs, a series of novel ethylene glycol derivatives of nitrofurantoin was synthesised and the in vitro antileishmanial efficacy of the compounds tested against Leishmania donovani and Leishmania major strains. Arylated ethylene glycol derivatives were found to be the most potent, with submicromolar activity up to 294-fold greater than the parent compound nitrofurantoin. Analogues 2j and 2k had the best antipromastigote activities with submicromolar IC50 values against L. major IR-173 and antimonial-resistant L. donovani 9515 strains.
Collapse
Affiliation(s)
- Keitumetsi Ndlovu
- Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa
| | - Christina Kannigadu
- Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa
| | - Janine Aucamp
- Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa
| | | | - David D N'Da
- Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa
| |
Collapse
|
6
|
Brioschi MBC, Coser EM, Coelho AC, Gadelha FR, Miguel DC. Models for cytotoxicity screening of antileishmanial drugs: what has been done so far? Int J Antimicrob Agents 2022; 60:106612. [PMID: 35691601 DOI: 10.1016/j.ijantimicag.2022.106612] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Revised: 04/28/2022] [Accepted: 05/14/2022] [Indexed: 11/19/2022]
Abstract
A growing number of studies have demonstrated the in vitro potential of an impressive number of antileishmanial candidates in the past years. However, the lack of uniformity regarding the choice of cell types for cytotoxicity assays may lead to uncomparable and inconclusive data. In vitro assays relying solely on non-phagocytic cell models may not represent a realistic result as the effect of an antileishmanial agent should ideally be presented based on its cytotoxicity profile against reticuloendothelial system cells. In the present review, we have assembled studies published in the scientific literature from 2015 to 2021 that explored leishmanicidal candidates, emphasising the main host cell models used for cytotoxicity assays. The pros and cons of different host cell types as well as primary cells and cell lines are discussed in order to draw attention to the need to establish standardised protocols for preclinical testing when assessing new antileishmanial candidates.
Collapse
Affiliation(s)
- Mariana B C Brioschi
- Department of Animal Biology-Parasitology Section, Biology Institute, State University of Campinas-UNICAMP, Campinas, São Paulo, Brazil
| | - Elizabeth M Coser
- Department of Animal Biology-Parasitology Section, Biology Institute, State University of Campinas-UNICAMP, Campinas, São Paulo, Brazil
| | - Adriano C Coelho
- Department of Animal Biology-Parasitology Section, Biology Institute, State University of Campinas-UNICAMP, Campinas, São Paulo, Brazil
| | - Fernanda R Gadelha
- Department of Biochemistry and Tissue Biology, Biology Institute, State University of Campinas-UNICAMP, Campinas, São Paulo, Brazil
| | - Danilo C Miguel
- Department of Animal Biology-Parasitology Section, Biology Institute, State University of Campinas-UNICAMP, Campinas, São Paulo, Brazil.
| |
Collapse
|
7
|
Badenhorst GD, Kannigadu C, Aucamp J, N'Da DD. Probing O-substituted Nifuroxazide analogues against Leishmania: Synthesis, in vitro efficacy, and hit/lead identification. Eur J Pharm Sci 2022; 176:106242. [PMID: 35732232 DOI: 10.1016/j.ejps.2022.106242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2022] [Revised: 06/07/2022] [Accepted: 06/18/2022] [Indexed: 11/03/2022]
Abstract
Leishmaniasis is a neglected tropical disease affecting millions of people worldwide, with 650 000 to 1.1 million new infections reported annually by the World Health Organization. Current antileishmanial treatments are unsatisfactory due to the development of parasitic resistance and the toxicity associated with the drugs used, and this highlights the need for the development of new antileishmanial drugs. In this study, a series of nifuroxazide analogues were synthesized in a single step reaction and investigated for their antileishmanial potential. The sulfonate 1l, bearing pyridine ring, was deemed an antileishmanial hit, targeting the amastigotes of Leishmania (L.) donovani and L. major, the pathogens of visceral and cutaneous leishmaniasis, respectively, with micromolar potencies. The benzyl analogues 2c and 2d were also confirmed as submicromolar active leads against amastigotes of L. major. These analogues stand as promising candidates for further investigation involving the evaluation of their in vivo activities and molecular targets.
Collapse
Affiliation(s)
- Gideon D Badenhorst
- School of Pharmacy, Faculty of Heath Sciences, North-West University, Potchefstroom 2520, South Africa
| | - Christina Kannigadu
- Drug Discovery, Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom 2520, South Africa
| | - Janine Aucamp
- Drug Discovery, Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom 2520, South Africa
| | - David D N'Da
- Drug Discovery, Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom 2520, South Africa.
| |
Collapse
|
8
|
Zuma NH, Aucamp J, Viljoen M, N'Da DD. Synthesis, in vitro Antileishmanial Efficacy and Hit/Lead Identification of Nitrofurantoin-Triazole Hybrids. ChemMedChem 2022; 17:e202200023. [PMID: 35388649 PMCID: PMC9322565 DOI: 10.1002/cmdc.202200023] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Revised: 04/04/2022] [Indexed: 11/09/2022]
Abstract
Leishmaniasis is a vector-borne neglected parasitic infection affecting thousands of individuals, mostly among populations in low- to moderate-income developing countries. In the absence of protective vaccines, the management of the disease banks solely on chemotherapy. However, the clinical usefulness of current antileishmanial drugs is threatened by their toxicity and the emergence of multidrug-resistant strains of the causative pathogens. This emphasizes the imperative for the development of new and effective antileishmanial agents. In this regard, we synthesized and evaluated in vitro the antileishmanial activity and cytotoxicity profile of a series of nitrofurantoin-triazole hybrids. The nitrofurantoin derivative 1 featuring propargyl moiety was distinctively the most active of all, was nontoxic to human cells and possessed submicromolar cellular activity selectively directed towards the pathogens of the life threatening visceral leishmaniasis. Hence it was identified as potential antileishmanial lead for further investigation into its prospective to act as alternative to therapies.
Collapse
Affiliation(s)
- Nonkululeko H. Zuma
- Centre of Excellence for Pharmaceutical Sciences (Pharmacen)Faculty of Health SciencesNorth-West University11 Hoffmann StreetPotchefstroom2520South Africa
| | - Janine Aucamp
- Centre of Excellence for Pharmaceutical Sciences (Pharmacen)Faculty of Health SciencesNorth-West University11 Hoffmann StreetPotchefstroom2520South Africa
| | - Maryna Viljoen
- School of Pharmacy, Faculty of Health SciencesNorth-West University11 Hoffmann StreetPotchefstroom2520South Africa
| | - David D. N'Da
- Centre of Excellence for Pharmaceutical Sciences (Pharmacen)Faculty of Health SciencesNorth-West University11 Hoffmann StreetPotchefstroom2520South Africa
| |
Collapse
|
9
|
Cohen A, Azas N. Challenges and Tools for In Vitro Leishmania Exploratory Screening in the Drug Development Process: An Updated Review. Pathogens 2021; 10:1608. [PMID: 34959563 PMCID: PMC8703296 DOI: 10.3390/pathogens10121608] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Revised: 12/03/2021] [Accepted: 12/07/2021] [Indexed: 12/13/2022] Open
Abstract
Leishmaniases are a group of vector-borne diseases caused by infection with the protozoan parasites Leishmania spp. Some of them, such as Mediterranean visceral leishmaniasis, are zoonotic diseases transmitted from vertebrate to vertebrate by a hematophagous insect, the sand fly. As there is an endemic in more than 90 countries worldwide, this complex and major health problem has different clinical forms depending on the parasite species involved, with the visceral form being the most worrying since it is fatal when left untreated. Nevertheless, currently available antileishmanial therapies are significantly limited (low efficacy, toxicity, adverse side effects, drug-resistance, length of treatment, and cost), so there is an urgent need to discover new compounds with antileishmanial activity, which are ideally inexpensive and orally administrable with few side effects and a novel mechanism of action. Therefore, various powerful approaches were recently applied in many interesting antileishmanial drug development programs. The objective of this review is to focus on the very first step in developing a potential drug and to identify the exploratory methods currently used to screen in vitro hit compounds and the challenges involved, particularly in terms of harmonizing the results of work carried out by different research teams. This review also aims to identify innovative screening tools and methods for more extensive use in the drug development process.
Collapse
Affiliation(s)
- Anita Cohen
- IHU Méditerranée Infection, Aix Marseille University, IRD (Institut de Recherche pour le Développement), AP-HM (Assistance Publique—Hôpitaux de Marseille), SSA (Service de Santé des Armées), VITROME (Vecteurs—Infections Tropicales et Méditerranéennes), 13005 Marseille, France;
| | | |
Collapse
|